MUC1 and neoplasm: After confirming MUC1 as a tumor specific antigen in recurrent HNSCC (Figure 1), for the first time we evaluated the safety and immunological potential of combining the MUC1 peptide/polyICLC vaccine with Tadalafil treatment.